



Construction of *Salmonella* vaccines

David Hone.

Department of Microbiology and Immunology
University of Adelaide,
Adelaide, 5000
Australia

A thesis Submitted for the degree of Doctor of Philosophy.
June, 1988.

1	Introduction	1
1.1	Humoral responses of the mucosa	2
1.1.1	Secretory IgA: its synthesis and transport into the intestinal lumen	2
1.1.2	The follicle-associated epithelium of Peyer's patches — antigen uptake and processing	3
	The parafollicular region interacts with the FAE	4
1.1.3	The Peyer's patches are an enriched source of IgA precursor cells	4
	Antigen induced differentiation of IgA precursor cells	4
	Migration and terminal differentiation of IgA ⁺ plasma cells	6
1.1.4	The common mucosal system	6
1.2	The function of secretory IgA	7
1.2.1	Inhibition of adherence prevents colonisation	7
1.2.2	Antitoxin activity prevents enterotoxins binding with their receptors	8
1.2.3	Antibacterial versus antitoxin immunity	9
1.2.4	The synergistic affects of anti-adherence and antitoxin responses	10
1.3	The cell mediated immune response	10
1.3.1	The involvement of macrophages in CMI	10
1.3.2	The involvement of T cells in CMI	12
1.3.3	DTH as a measure of CMI	13
1.3.4	Involvement of antibody in CMI	14
1.3.5	Local CMI of the intestine	15
1.3.6	Other mechanisms of intestinal CMI	15
1.3.7	The functional role of the diffuse lymphoidal compartment in intestinal immunity	16
	The lamina propria is enriched with effector cells	16

	The intraepithelial lymphoid cells interact directly with the intestinal lumen	18
1.4	Elicitation of Immunity by Vaccination	19
1.4.1	Parenteral vaccines	19
	Controlled field trials with parenteral vaccines	20
	Parenteral vaccination boosts preexisting immunity	21
	Future prospects of parenteral vaccines	22
1.5	Vaccination by peroral administration	22
1.5.1	Inactivated oral vaccines	22
	Combination cholera vaccines	23
	Future improvement of B-WCV	25
	Inactivated oral typhoid vaccines	26
	Factors which affect the success of inactivated oral vaccines	26
1.5.2	Live oral vaccines	27
	Spontaneously derived attenuated variants	29
	Hybrid derivatives of <i>Shigella</i>	32
	Live vaccines derived by non-specific mutagenesis	33
	Vaccines constructed by modern genetic techniques	39
1.5.3	Construction of bivalent live oral vaccines	43
	Stability of the heterologous antigen	44
	Choice of bacterial carrier strain	45
1.6	Aims of this thesis	48
2	Materials and Methods	49
2.1	Materials	49
2.2	Methods	51
2.2.1	Media	51
2.2.2	Bacteria and bacteriophage	52
2.2.3	Plasmid vectors	52
2.2.4	Maintenance of bacterial strains	52

2.2.5	Selection of bacteria spontaneously cured of a plasmid specifying Sp-resistance	53
2.2.6	Selection of histidine auxotrophic mutants by Ap enrichment	53
2.2.7	Selection of spontaneous <i>via</i> mutants	54
2.2.8	Selection of bacteriophage Felix-O-resistant mutants	54
2.2.9	Selection of rifampicin-resistant (<i>rif</i>) mutants	54
2.2.10	Genetic stability of <i>gal</i> mutants	55
2.2.11	Sensitivity of strains to galactose-induced lysis	55
2.2.12	Determination of Leloir pathway enzyme levels	55
2.2.13	Determination of the <i>in vitro</i> stability of K88 expression	56
2.2.14	Preparation of K88 antigen	56
2.2.15	Lambda 1059 methods	57
2.2.16	Tests for bacteriophage sensitivity	57
2.2.17	Phage P22 mediated transduction and bacterial transformation	57
2.2.18	Preparation of formalin-inactivated cells	58
2.2.19	Transposition with Tn1725	58
2.2.20	Minicell Procedures	59
2.2.21	Lipopolysaccharide preparation prior to SDS-PAGE	59
2.2.22	Deoxyribonucleic acid (DNA) methods	60
	DNA enzyme reactions	60
	DNA preparation	61
	Agarose gel electrophoresis (AGE)	61
	DNA labelling, Southern transfers, and DNA blotting	62
	DNA quantitation	62
2.2.23	Electrophoresis and analysis of proteins and LPS	62
	SDS-polyacrylamide gel electrophoresis (SDS-PAGE)	62
	Protein staining	62
	Protein size determination	63
	Lipopolysaccharide-specific silver staining	63

Western transfer	63
Colony transfer	63
Immunoblotting	63
2.2.24 Preparation of serum	64
Absorption of serum with bacteria	64
2.2.25 Hemagglutination (HA) inhibition assay	65
2.2.26 Enzyme Linked Immunosorbent Assay (ELISA)	65
Human immune responses to <i>S. typhi</i>	65
Mouse immune responses to K88 bearing strains	66
2.2.27 ELISA inhibition assay (EIA)	66
2.2.28 Bactericidal assay	67
2.2.29 Serum sensitivity of various strains	67
2.2.30 Animal Experiments	68
Preparation of bacteria for injection	68
Mice	68
Bacterial virulence by the intraperitoneal (ip) or oral route	68
Mouse mucin virulence assay	68
Comparison of vaccine potential	69
Enumeration of bacteria in infected animals	69
2.2.31 Volunteer trial	70
Volunteers	70
Administration of the vaccine	71
Sampling of serum and intestinal fluid	71
Stool samples	71
Blood cultures	71
3 Cloning of the <i>gal</i> operon of <i>Salmonella typhimurium</i>	72
3.1 Introduction	72
3.2 Results	74
3.2.1 Isolation of clones of the <i>gal</i> operon	74

3.2.2	Subcloning of the <i>gal</i> DNA from λ B1.2	75
3.2.3	Localisation of the <i>gal</i> genes in the cloned DNA of pADE107	75
	Transposon mutagenesis	75
	Minicell analysis of the genes encoded by pADE107	76
3.3	Discussion	78
3.4	Conclusion	80
4	Introduction of defined <i>galE</i> deletions into <i>Salmonella</i> strains, to construct strains for use as live oral vaccines	81
4.1	Introduction	81
4.2	Results	84
4.2.1	Construction of a plasmid bearing the <i>galE</i> -H1 mutation	84
4.2.2	Integrating <i>galE</i> -H1 into the chromosome of <i>Salmonella</i> strains	84
4.2.3	Chromosomal DNA blotting	85
4.2.4	Physical characteristics of the <i>galE</i> deletion strains.	86
	Reversion of the <i>galE</i> -H1 mutation	86
	Growth rates	86
	Resistance to lyophilisation	86
	Synthesis of smooth LPS	87
	Presence of the 90kb virulence plasmid	87
4.2.5	Further characterisation of strains LT2H1 and C5H1	87
	Susceptibility to galactose-induced lysis	87
	Sensitivity to bacteriophage P22 and Felix-O	88
	Sensitivity to killing by serum	88
4.2.6	Virulence, immunogenicity, and <i>in vivo</i> persistence of strains LT2H1 and C5H1 in mice	88
	Virulence and immunogenicity of LT2H1 and C5H1 in mice	88
	<i>In vivo</i> persistence of LT2H1 and C5H1 in mice	89
4.3	Discussion	89

4.4	Conclusion	90
5	A <i>galE</i>, <i>via</i> (Vi-negative) mutant of <i>Salmonella typhi</i> Ty2 retains virulence in man	91
5.1	Introduction	91
5.2	Results	97
5.2.1	Comparison of <i>S. typhi</i> with its <i>galE</i> and <i>via</i> derivatives .	97
	Derivation of strains Ty2Vi and EX462	97
	Biochemical reactions	97
	Outer-membrane properties	98
	Resistance to serum and <i>in vivo</i> killing	98
5.2.2	Virulence and immunogenicity in mice	99
	Virulence	99
	Immunogenicity	100
5.2.3	Safety and immunogenicity in humans	100
	Safety	100
	Immunogenicity	101
5.2.4	Characteristics of bacteria isolated from blood culture . .	102
5.3	Discussion	102
5.4	Conclusion	105
6	A chromosomal integration system for stabilisation of heterologous genes in <i>Salmonella</i> based vaccine strains	106
6.1	Introduction	106
6.2	Results	108
6.2.1	Plasmid construction	108
	Overview of method	108
	Cloning <i>hisOGD</i> from <i>S. typhimurium</i>	108
	Construction of a <i>hisOG</i> deletion in pADE171	109
	Cloning the K88 genes from pFM205 into pADE171	109

6.2.2	Integration of the K88 genes into the chromosome of <i>Salmonella typhimurium</i>	110
6.2.3	Expression and <i>in vitro</i> stability of chromosomally integrated K88 genes	111
	Expression of chromosomal K88 genes	111
	<i>In vitro</i> stability	112
6.2.4	Colonisation, stability, and immunogenicity of recombinant strains bearing K88 fimbriae in mice	112
	Peyer's patch colonisation	112
	Stability of K88-bearing strains in mice	113
	Immunogenicity	114
	Vaccine potential of J754 against <i>Salmonella</i> challenge . .	114
6.3	Discussion	114
6.4	Conclusion	118
7	Discussion	119
7.1	Aims of thesis	119
7.2	Conclusions	120
7.3	Future development of live oral typhoid vaccines	123
	Bibliography	126

Abstract

In this thesis the molecular cloning of the *gal* operon of *Salmonella typhimurium* LT2, the localisation of the *gal* promoter, and the *gal* genes: *galE*, *galT*, and *galK*, are described. The order of the genes and the direction of transcription was the same as occurs in *E. coli* K12 (promoter, *galE*, *galT*, *galK*). A restriction enzyme map of the operon was obtained and the termini of the three genes were precisely located by means of transposon insertion mutagenesis and minicell analysis of the *gal* proteins expressed by various plasmids.

A plasmid which contained a defined 0.4 kilobase deletion in the *galE* gene, but which still expressed *galT* and *galK* activities from the *gal* promoter was constructed. The *galE* deletion was recombined into the chromosomal *gal* operons of *S. typhimurium* and *Salmonella typhi* Ty2. The resulting strains were vigorous, non-reverting *galE* mutants which were sensitive to galactose-induced lysis at 0.06mM galactose. The *S. typhimurium galE* derivatives were avirulent and protective in mice whereas a *galE* mutant of *S. typhi* Ty2 (Ty2H1) was only partially attenuated in mice.

A rifampicin-resistant, Vi-negative (*via*) derivative of Ty2H1, strain EX462, was selected. Compared with the Ty2 parent strain, EX462 was serum-sensitive and highly attenuated in the mouse mucin virulence assay. When four human volunteers ingested 7×10^8 viable EX462, two became ill and developed a typhoid-like disease with fever and bacteremia. Blood isolates from these individuals were indistinguishable from the vaccine strain using a variety of criteria. We concluded that, even in a *via* background, the *galE* mutation was not attenuating for *S. typhi* in man.

A system was developed, whereby heterologous DNA encoding a protective antigen from an enteropathogen may be recombined into the chromosome of attenuated *Salmonella* carrier strains. This system involved: i) integration of a *hisOG* deletion mutation into the chromosome; ii) replacement of the *hisOG* deletion by the complete *hisOG* region and the segment of heterologous DNA

which encodes the antigen of interest. Recombinants were selected *his*⁺. This system was used to integrate the pilin-encoding K88 genes of porcine enterotoxigenic *Escherichia coli* into the chromosome of a *galE* mutant of *S. typhimurium* (LT2H1). Recombinants were detected at a frequency of between 1.0×10^{-3} and 1.5×10^{-3} . A variety of tests confirmed that the K88 genes were integrated into the chromosome of LT2H1 and were expressed. The stability of the recombinant was tested both *in vivo* and *in vitro*. When administered orally to mice, the recombinant elicited a serum antibody response to K88, and retained the vaccine potential of the vector strain.